Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting
Key Highlights
- ➤OMNI Ultra (SGHT) commercially available as latest implant-free glaucoma surgery system
- ➤OMNI Ultra enables single-pass canaloplasty followed by trabeculotomy
- ➤OMNI Ultra addresses trabecular meshwork, Schlemm’s canal, and collector channels
- ➤OMNI Ultra launches at 2026 AAO annual meeting October 9-12
- ➤Clearance Assistant Plus previews for TearCare meibomian gland expression and debridement
Expert Statements
Zarmeena Vendal, Cataract and Glaucoma Surgeon and Owner at Westlake Eye Specialists
“Sight Sciences has not only been a thought leader in the advancement of the implant-free interventional glaucoma category, they have gone one step further with their commitment to continued innovation”
Zarmeena Vendal, Cataract and Glaucoma Surgeon and Owner at Westlake Eye Specialists
“The OMNI Ultra is the latest example of this commitment. I have relied on the OMNI Surgical System for 8 years now and can still appreciate how OMNI Ultra builds on a proven technology platform with even more versatility and procedural flexibility. This addresses the needs of a broader range of surgeons, and this is a key to moving interventional glaucoma forward.”
Paul Badawi, CEO and co-founder of Sight Sciences
“AAO represents an important opportunity to showcase our enhanced product portfolio for physicians and industry leaders, and we are excited to launch OMNI Ultra at the meeting this year”
Paul Badawi, CEO and co-founder of Sight Sciences
“At Sight Sciences, we remain steadfast in our mission to equip eyecare providers with versatile, efficacious technologies that address the root cause of disease through procedural intervention. The launch of OMNI Ultra, which was expertly designed through direct collaboration with our surgeon customers, reflects our deep commitment to advancing our comprehensive, implant-free, interventional glaucoma platform.”
MENLO PARK, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, interventional technologies intended to transform eye care and improve patients’ lives, today announced the commercial availability of the OMNI(®) Ultra Surgical System (OMNI Ultra), an expansion of its pioneering ab interno canaloplasty platform. The new technology will be featured at this year’s American Academy of Ophthalmology (AAO) annual meeting held on October 9-12 in New Orleans, Louisiana.
“Sight Sciences has not only been a thought leader in the advancement of the implant-free interventional glaucoma category, they have gone one step further with their commitment to continued innovation,” said Dr. Zarmeena Vendal, Cataract and Glaucoma Surgeon, Owner at Westlake Eye Specialists, and OMNI Ultra pre-launch user. “The OMNI Ultra is the latest example of this commitment. I have relied on the OMNI Surgical System for 8 years now and can still appreciate how OMNI Ultra builds on a proven technology platform with even more versatility and procedural flexibility. This addresses the needs of a broader range of surgeons, and this is a key to moving interventional glaucoma forward.”
Get started
Create a free account to read the full story.